AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26231663 — intervention group
Group type: COMPARATOR
Intervention: 0.0g/kg (placebo) alcohol
Number of subjects: 0
Study 23623224 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic colectomy (LC); 38% of patients initiated as laparoscopic procedures, including 25% laparoscopic, 32% laparoscopic assisted, 26% hand assisted, and 16% converted to open colectomy.
Number of subjects: 3393
Study 23623224 — intervention group
Group type: COMPARATOR
Intervention: Open colectomy (OC); 62% of patients underwent OC.
Number of subjects: 3393
Study 22019457 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate aerobic exercise training
Number of subjects: 19
Study 19791828 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 2.5 or 5 mg once daily
Number of subjects: 0
Study 19791828 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg once daily plus metformin
Number of subjects: 0
Study 19791828 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 2.5 or 5 mg once daily added to metformin, glyburide, or a thiazolidinedione
Number of subjects: 0
Study 19791828 — intervention group
Group type: COMPARATOR
Intervention: Saxagliptin
Number of subjects: 0
Study 16873892 — intervention group
Group type: COMPARATOR
Intervention: HP-hMG
Number of subjects: 731
Study 16873892 — intervention group
Group type: EXPERIMENTAL
Intervention: rFSH
Number of subjects: 731
Study 15373926 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioadhesive tablet 100 mg
Number of subjects: 18
Study 15373926 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioadhesive tablet 50 mg
Number of subjects: 18
Study 15373926 — intervention group
Group type: COMPARATOR
Intervention: Oral gel (375 mg, 3 times a day)
Number of subjects: 18
Study 11740230 — intervention group
Group type: EXPERIMENTAL
Intervention: NaCl therapy (2 mmol/kg/d for 7 days)
Number of subjects: 57
Study 11740230 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO3 therapy (2 mmol/kg/d for 7 days)
Number of subjects: 57
Study 11740230 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal urine pH)
Number of subjects: 57
Study 9386652 — intervention group
Group type: EXPERIMENTAL
Intervention: AC-17 (300 mg on days 1-2, 150 mg on day 3)
Number of subjects: 95
Study 9386652 — intervention group
Group type: COMPARATOR
Intervention: Placebo (B vitamins)
Number of subjects: 95
Study 9386652 — intervention group
Group type: EXPERIMENTAL
Intervention: AC-17
Number of subjects: 95
Study 9386652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 7970686 — intervention group
Group type: EXPERIMENTAL
Intervention: Actively mobilized patients with postural correlation and mobilization techniques
Number of subjects: 0
Study 7970686 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (rest and analgesia)
Number of subjects: 0
Study 7970686 — intervention group
Group type: COMPARATOR
Intervention: Mobilization programmes (not specified in detail)
Number of subjects: 0
Study 3104753 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychometric study of psychological adjustment in ALS patients
Number of subjects: 0
Study 3104753 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of trends in psychological adjustment during a pilot clinical trial
Number of subjects: 0
Study 29547881 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHA-PQ) every 8 weeks
Number of subjects: 300
Study 29547881 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHA-PQ) every 4 weeks
Number of subjects: 300
Study 29547881 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine every 8 weeks
Number of subjects: 300
Study 27435883 — intervention group
Group type: EXPERIMENTAL
Intervention: Affiliation disclosure on health organization's Facebook post
Number of subjects: 674
Study 27435883 — intervention group
Group type: EXPERIMENTAL
Intervention: Affiliation cue next to commenters' names
Number of subjects: 674
Study 27435883 — intervention group
Group type: EXPERIMENTAL
Intervention: Cues indicating health organization removed user-generated comments
Number of subjects: 674
Study 25308537 — intervention group
Group type: EXPERIMENTAL
Intervention: Kneeling posture using a kneeling stool
Number of subjects: 33
Study 25308537 — intervention group
Group type: COMPARATOR
Intervention: Standing posture on a step stool with bed height adjustment
Number of subjects: 33
Study 22907567 — intervention group
Group type: EXPERIMENTAL
Intervention: Laninamivir octanoate
Number of subjects: 203
Study 22907567 — intervention group
Group type: COMPARATOR
Intervention: Oseltamivir
Number of subjects: 203
Study 20825257 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycolic acid (GA) peels
Number of subjects: 24
Study 20825257 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino fruit acid (AFA) peels
Number of subjects: 24
Study 20825257 — intervention group
Group type: COMPARATOR
Intervention: Comparison of GA and AFA peels
Number of subjects: 24
Study 18445362 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg once daily for 9 weeks
Number of subjects: 38
Study 18445362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 18445362 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 38
Study 18445362 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone and Placebo
Number of subjects: 38
Study 15745761 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide
Number of subjects: 1081
Study 15745761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1081
Study 12515743 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-methylprednisolone (6‐MP; 1 mg/kg BID for 2 days)
Number of subjects: 12
Study 12515743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11030292 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH 1 microg/kg plus GHRP-6 1 microg/kg intravenously
Number of subjects: 250
Study 11030292 — intervention group
Group type: COMPARATOR
Intervention: Insulin tolerance test (ITT)
Number of subjects: 250
Study 11030292 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH/GHRP-6 test
Number of subjects: 250
Study 8967668 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (10 micrograms/kg of body weight) for 18 months
Number of subjects: 32
Study 8967668 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone
Number of subjects: 32
Study 1657221 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylphenidate
Number of subjects: 20
Study 1657221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7038157 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (180 or 240 mg/day)
Number of subjects: 3837
Study 7038157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3837
Study 30306325 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual fentanyl tablet
Number of subjects: 100
Study 30306325 — intervention group
Group type: COMPARATOR
Intervention: Oral piroxicam fast-dissolving tablets
Number of subjects: 100
Study 28109872 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus-eluting stent (R-ZES)
Number of subjects: 7618
Study 28109872 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-antiplatelet therapy
Number of subjects: 7618
Study 25773712 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide 2.5 µg
Number of subjects: 20
Study 25773712 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide 5 µg
Number of subjects: 20
Study 25773712 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide 10 µg
Number of subjects: 20
Study 25773712 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide 20 µg
Number of subjects: 20
Study 25773712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 25773712 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide (all doses)
Number of subjects: 20
Study 25773712 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide (≥5 µg)
Number of subjects: 20
Study 24379001 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoriasis (time-varying covariate)
Number of subjects: 7099
Study 24379001 — intervention group
Group type: EXPERIMENTAL
Intervention: Propensity-matched analysis
Number of subjects: 7099
Study 24379001 — intervention group
Group type: COMPARATOR
Intervention: Patients without psoriasis
Number of subjects: 7099
Study 22842354 — intervention group
Group type: EXPERIMENTAL
Intervention: Information arm (principals received information about anaemia)
Number of subjects: 3553
Study 22842354 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsidy arm (principals received information and unconditional subsidies)
Number of subjects: 3553
Study 22842354 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive arm (principals received information, subsidies, and financial incentives)
Number of subjects: 3553
Study 22842354 — intervention group
Group type: EXPERIMENTAL
Intervention: Information arm with pre-existing academic performance incentives
Number of subjects: 3553
Study 22842354 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive arm with pre-existing academic performance incentives
Number of subjects: 3553
Study 22842354 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 3553
Study 19610055 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 12.5 mg once daily
Number of subjects: 152
Study 19610055 — intervention group
Group type: COMPARATOR
Intervention: Variceal band ligation (VBL) every 2 weeks until eradication
Number of subjects: 152
Study 17463195 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-based psychoeducational intervention
Number of subjects: 46
Study 17463195 — intervention group
Group type: COMPARATOR
Intervention: Information-only control condition
Number of subjects: 46
Study 15262104 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive management
Number of subjects: 111
Study 15262104 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 111
Study 16227892 — intervention group
Group type: EXPERIMENTAL
Intervention: Autograft laminectomy bone with calcium sulfate (test side)
Number of subjects: 74
Study 16227892 — intervention group
Group type: COMPARATOR
Intervention: Iliac crest bone graft (control side)
Number of subjects: 74
Study 10234561 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 68
Study 10234561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 8607747 — intervention group
Group type: EXPERIMENTAL
Intervention: Postacute brain injury rehabilitation (PABIR)
Number of subjects: 0
Study 8607747 — intervention group
Group type: COMPARATOR
Intervention: Natural recovery after brain injury
Number of subjects: 0
Study 1656740 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg on day 1, followed by 250 mg on days 2-5)
Number of subjects: 546
Study 1656740 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor (500 mg three times daily for 10 days)
Number of subjects: 546
Study 1656740 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 546
Study 1656740 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 546
Study 7047863 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone (Deltasone)
Number of subjects: 9
Study 7047863 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (Delta‐cortef)
Number of subjects: 9
Study 7047863 — intervention group
Group type: COMPARATOR
Intervention: Intravenous prednisolone (Hydeltrasol)
Number of subjects: 9
Study 7047863 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone and oral prednisolone
Number of subjects: 9
Study 31304694 — intervention group
Group type: EXPERIMENTAL
Intervention: Wagon group
Number of subjects: 80
Study 31304694 — intervention group
Group type: COMPARATOR
Intervention: Stretcher group
Number of subjects: 80
Study 30447165 — intervention group
Group type: COMPARATOR
Intervention: Conventional oral hygiene care programme (COHCP): manual toothbrushing with oral hygiene instruction (OHI)
Number of subjects: 94
Study 30447165 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced oral hygiene care programme (AOHCP): powered toothbrushing, mouthrinsing with chlorhexidine and OHI
Number of subjects: 94
Study 29072476 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT) administration
Number of subjects: 0
Study 29072476 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 27423374 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-guided group ICBT (GT)
Number of subjects: 149
Study 27423374 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-guided individual ICBT (IT)
Number of subjects: 149
Study 27423374 — intervention group
Group type: COMPARATOR
Intervention: Wait-list (WL)
Number of subjects: 149
Study 24285844 — intervention group
Group type: EXPERIMENTAL
Intervention: gD-2 HSV vaccine adjuvanted with ASO4
Number of subjects: 8323
Study 24285844 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellular immune responses
Number of subjects: 8323
Study 22349765 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (5 g/d for 12 weeks)
Number of subjects: 10
Study 20814825 — intervention group
Group type: EXPERIMENTAL
Intervention: Cysteamine treatment
Number of subjects: 14
Study 17947936 — intervention group
Group type: EXPERIMENTAL
Intervention: OPCAB
Number of subjects: 20
Study 17947936 — intervention group
Group type: COMPARATOR
Intervention: CCAB
Number of subjects: 20
Study 16125534 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/d)
Number of subjects: 27
Study 16125534 — intervention group
Group type: COMPARATOR
Intervention: No-drug
Number of subjects: 27
Study 12171820 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportional Assist Ventilation (PAV)
Number of subjects: 18
Study 12171820 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 18
Study 12171820 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous Breathing (SB)
Number of subjects: 18
Study 10573633 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micrograms/kg of rocuronium
Number of subjects: 45
Study 10573633 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 micrograms/kg of rocuronium
Number of subjects: 45
Study 10573633 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 micrograms/kg of rocuronium
Number of subjects: 45
Study 10573633 — intervention group
Group type: COMPARATOR
Intervention: Control height (T1:T0)
Number of subjects: 45
Study 10573633 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of rocuronium (400, 600, 800 micrograms/kg)
Number of subjects: 45
Study 10573633 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of rocuronium
Number of subjects: 45
Study 8589028 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan, administered at 1.5 mg/m2/day IV x 5 days every 3 weeks
Number of subjects: 32
Study 8589028 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan
Number of subjects: 32
Study 31070940 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to fine particulate matter during the fifth and sixth postnatal years
Number of subjects: 2221
Study 31070940 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to higher fine particulate matter levels during the prenatal period and from the fourth postnatal year
Number of subjects: 2221
Study 31070940 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative effect of a fine particulate matter increase
Number of subjects: 2221
Study 29442276 — intervention group
Group type: EXPERIMENTAL
Intervention: ABRAS score (derived from ALBI grade, BCLC stage, response after first TACE, Alpha-fetoprotein level, sex)
Number of subjects: 476
Study 29442276 — intervention group
Group type: EXPERIMENTAL
Intervention: ALBI grade
Number of subjects: 476
Study 29442276 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival prediction model
Number of subjects: 476
Study 27370359 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant hormonal treatment with a long-acting GnRH agonist for 3 months (Group A)
Number of subjects: 120
Study 27370359 — intervention group
Group type: COMPARATOR
Intervention: Classical long protocol IVF stimulation (Group B)
Number of subjects: 120
Study 25200848 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous hemofiltration
Number of subjects: 68
Study 25200848 — intervention group
Group type: COMPARATOR
Intervention: Periprocedural hemofiltration
Number of subjects: 68
Study 22739669 — intervention group
Group type: COMPARATOR
Intervention: Er,Cr:YSGG laser at 8.5 J/cm2
Number of subjects: 264
Study 22739669 — intervention group
Group type: COMPARATOR
Intervention: Acidulated phosphate fluoride gel (APF gel, 1.23% F) for 4 min
Number of subjects: 264
Study 22739669 — intervention group
Group type: COMPARATOR
Intervention: Combination of Er,Cr:YSGG laser and APF gel
Number of subjects: 264
Study 22739669 — intervention group
Group type: COMPARATOR
Intervention: Er,Cr:YSGG laser at 2.8 J/cm2 and 5.6 J/cm2
Number of subjects: 264
Study 22739669 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 264
Study 19192427 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemic control targeting hemoglobin A(1c) below 6%
Number of subjects: 0
Study 19192427 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemic control among newly diagnosed type 2 diabetes patients
Number of subjects: 0
Study 19192427 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended hemoglobin A(1c) target of below 7%
Number of subjects: 0
Study 17544857 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 131
Study 17544857 — intervention group
Group type: COMPARATOR
Intervention: Relaxation
Number of subjects: 131
Study 15060257 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral creatine supplementation (CS) 200 mg/kg per day
Number of subjects: 34
Study 15060257 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 34
Study 11552347 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurophysiologically-based model for enhancing single trial evoked potentials (EPs) using adaptive filtering and a genetic algorithm.
Number of subjects: 0
Study 11552347 — intervention group
Group type: COMPARATOR
Intervention: Visual evoked potentials obtained by flashing light through closed eyelids.
Number of subjects: 0
Study 9758317 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g every 12 hours
Number of subjects: 12
Study 9758317 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g continuous infusion over 24 hours
Number of subjects: 12
Study 9758317 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g continuous infusion over 24 hours
Number of subjects: 12
Study 9758317 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g continuous infusion plus gentamicin 2 mg/kg
Number of subjects: 12
Study 7851106 — intervention group
Group type: EXPERIMENTAL
Intervention: Moricizine
Number of subjects: 0
Study 7851106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3262516 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 62
Study 3262516 — intervention group
Group type: COMPARATOR
Intervention: Sham TENS
Number of subjects: 62
Study 29724606 — intervention group
Group type: EXPERIMENTAL
Intervention: Informant labeled as 'teacher' presenting a large sample (n=5) or diverse range of exemplars.
Number of subjects: 99
Study 29724606 — intervention group
Group type: COMPARATOR
Intervention: Informant labeled as 'child' presenting a small sample (n=2) or homogeneous range of exemplars.
Number of subjects: 99
Study 29724606 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger children (3.42 years) trusting the informant labeled as 'teacher'.
Number of subjects: 99
Study 29724606 — intervention group
Group type: EXPERIMENTAL
Intervention: Older children (5.54 years) trusting the informant providing a large or diverse sample.
Number of subjects: 99
Study 28746232 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical thiocolchicoside (TCC 0.25%) foam 3 times daily
Number of subjects: 23
Study 28746232 — intervention group
Group type: COMPARATOR
Intervention: No topical thiocolchicoside (No-TCC)
Number of subjects: 23
Study 25894106 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback (NFB) plus pharmacotherapy
Number of subjects: 100
Study 25894106 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy alone (Control)
Number of subjects: 100
Study 23265945 — intervention group
Group type: EXPERIMENTAL
Intervention: Four rounds of oral visual inspection by trained health workers at 3-year intervals
Number of subjects: 191873
Study 23265945 — intervention group
Group type: COMPARATOR
Intervention: Routine care and one round of visual screening during 2006-2009
Number of subjects: 191873
Study 20980456 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxidized LDL (oxLDL) in circulating immune complexes
Number of subjects: 479
Study 20980456 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced glycation end products-modified LDL (AGE-LDL) in circulating immune complexes
Number of subjects: 479
Study 20980456 — intervention group
Group type: COMPARATOR
Intervention: LDL-C
Number of subjects: 479
Study 20980456 — intervention group
Group type: COMPARATOR
Intervention: Diastolic blood pressure
Number of subjects: 479
Study 20980456 — intervention group
Group type: COMPARATOR
Intervention: A1C
Number of subjects: 479
Study 18320411 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) during either one session (3 h) or five sessions (1 h each)
Number of subjects: 40
Study 16736120 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro Seal™ with Assure™
Number of subjects: 300
Study 16736120 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro Seal™ with self-etching primer IDEAL 1®
Number of subjects: 300
Study 16736120 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro Seal™ with First Step™ SEP
Number of subjects: 300
Study 16736120 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro Seal™
Number of subjects: 300
Study 16736120 — intervention group
Group type: COMPARATOR
Intervention: No Pro Seal™ with self-etching primer IDEAL 1®
Number of subjects: 300
Study 14552533 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal conditions
Number of subjects: 0
Study 14552533 — intervention group
Group type: EXPERIMENTAL
Intervention: Central nervous system pathology
Number of subjects: 0